|
|
Article: Omalizumab appears effective in patients with poorly controlled allergic asthma
- Article from:
- Formulary
- Article date:
- April 1, 2003
- Author:
CopyrightCopyright Advanstar Communications, Inc. Apr 2003. Provided by ProQuest LLC. (Hide copyright information)
|
DENVER, COLO-Patients whose asthma was poorly controlled with conventional treatments and who received the investigational anti-immunoglobulin-E drug omalizumab experienced about half the number of asthma deterioration-related incidents as patients who did not receive the add-on medication.
Rob Niven, MD, a respiratory consultant at the North West Lung Research Centre, Manchester, United Kingdom, said that in the yearlong open-label study, patients receiving add-on omalizumab had an annualized rate of 4.92 events per patient year, compared with 9.76 per patient year for patients who continued to receive baseline treatment for their asthma (P<.001).
In his presentation at the 60th ...